Rome, Nov 10. (Adnkronos Health) – “We must leverage what we have good and modernize it. We have one of the best healthcare systems in the world, but the services it provides are still designed for a population that in the Seventies and Eighties was very different from the current one. The Italian population is one of the oldest in the world, and those over sixty represent more than a quarter of the total. Keeping them healthy is not only an ethical duty but also a benefit for our economy.” This was stated by Antonino Biroccio, president and CEO of Gsk Italia, speaking at the XXI edition of the Meridiano Sanità Forum, ‘Health and life sciences: governing transitions, building the future’, the healthcare think tank of The European House – Ambrosetti, held today in Rome.
“Today we have technologies that allow us to prevent diseases in fragile adults and others that allow us to treat even without hospitalization – continues Biroccio – These are innovations often with a significant price, but which can save healthcare costs: this is what I call ‘real innovation’, that is, innovation that brings demonstrated advantages for the NHS. Two examples are the vaccination of fragile adults and new therapies in oncology, which can avoid hospitalizations and reduce ancillary costs.”
For Biroccio, the theme of the competitiveness and attractiveness of the Country System is then fundamental: “Investing in the Italian biopharmaceutical industry means contributing to the Italian economy, as well as to people’s health. For this reason, it is important to support it with less dispersed and more focused policies on priorities, as happens in other European countries,” he concluded.